Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy
Objective - to study the dynamics of clinical and laboratory parameters of inflammatory activity of the disease and cytokines in rheumatoid arthritis (RA) patients on a background of tofacitinib (TOFA) treatment.Material and methods. Ten patients with a reliable diagnosis of RA have been examined: p...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2021-12-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3103 |
| _version_ | 1797862580446822400 |
|---|---|
| author | N. A. Lapkina A. A. Baranov N. E. Abaytova N. Yu. Levshin A. S. Avdeyeva E. A. Leontyeva A. S. Artyukhov E. L. Nasonov |
| author_facet | N. A. Lapkina A. A. Baranov N. E. Abaytova N. Yu. Levshin A. S. Avdeyeva E. A. Leontyeva A. S. Artyukhov E. L. Nasonov |
| author_sort | N. A. Lapkina |
| collection | DOAJ |
| description | Objective - to study the dynamics of clinical and laboratory parameters of inflammatory activity of the disease and cytokines in rheumatoid arthritis (RA) patients on a background of tofacitinib (TOFA) treatment.Material and methods. Ten patients with a reliable diagnosis of RA have been examined: patients' age was 51.0 (48.0; 62.0) years, duration of disease was 7.0 (3.0; 20.0) years. All patients had high disease activity: DAS28 -5.88 (5.53; 5.94), CDAI - 33.0 (29.0; 36.0), SDAI - 33.72 (30.75; 36.85). All patients were treated with TOFA at a dose of 5 mg 2 times a day on a background of methotrexate therapy, non-steroidal anti-inflammatory drugs, and glucocorticoids. Observations were performed before treatment and after 3 and 6 months of therapy. Serum levels of 15 cytokines (IL-1β, IL-4, IL-6, TNF-α, INF-γ, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, sCD40L) were examined using multiplex xMAP technology.After 3 and 6 months of TOFA therapy, there was a significant decrease in DAS28 of 4.55 (3.47; 5.16) and 3.92 (3.80; 4.60); CDAI - 16.5 (11.0; 23.0) and 18.0 (15.0; 19.0); SDAI - 16.6 (11.23; 23.06) and 18.07 (15.06; 19.10); ESR - 19.0 (11.0; 26.0) and 7.0 (4.0; 18.0); CRP - 0.56 (0.50; 1.99) and 0.71 (0.51; 1.1) respectively. IL-6 levels decreased after 3 and 6 months of therapy (p<0.05). The concentration of INF-γ significantly decreased after 3 months (p<0.05), but remained unchanged thereafter. Concentrations of IL-25 and IL-31 decreased after 3 months (p<0.05), and by the 6th month of treatment there was an increase, however, not reaching the initial values.Conclusion. The results of the study show the efficacy of TOFA in RA and create prerequisites for further study of the cytokine-dependent mechanisms of inflammation in this disease. |
| first_indexed | 2024-04-09T22:21:39Z |
| format | Article |
| id | doaj.art-6489766af9a84ffebcd43d1d7fb6748d |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:21:39Z |
| publishDate | 2021-12-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-6489766af9a84ffebcd43d1d7fb6748d2023-03-22T13:45:57ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922021-12-0159669369910.47360/1995-4484-2021-693-6992767Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapyN. A. Lapkina0A. A. Baranov1N. E. Abaytova2N. Yu. Levshin3A. S. Avdeyeva4E. A. Leontyeva5A. S. Artyukhov6E. L. Nasonov7Yaroslavl State Medical UniversityYaroslavl State Medical UniversityYaroslavl State Medical UniversityYaroslavl State Medical UniversityV.A. Nasonova Research Institute of RheumatologyYaroslavl State Medical UniversityN.I. Pirogov Russian National Research Medical UniversityV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Objective - to study the dynamics of clinical and laboratory parameters of inflammatory activity of the disease and cytokines in rheumatoid arthritis (RA) patients on a background of tofacitinib (TOFA) treatment.Material and methods. Ten patients with a reliable diagnosis of RA have been examined: patients' age was 51.0 (48.0; 62.0) years, duration of disease was 7.0 (3.0; 20.0) years. All patients had high disease activity: DAS28 -5.88 (5.53; 5.94), CDAI - 33.0 (29.0; 36.0), SDAI - 33.72 (30.75; 36.85). All patients were treated with TOFA at a dose of 5 mg 2 times a day on a background of methotrexate therapy, non-steroidal anti-inflammatory drugs, and glucocorticoids. Observations were performed before treatment and after 3 and 6 months of therapy. Serum levels of 15 cytokines (IL-1β, IL-4, IL-6, TNF-α, INF-γ, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, sCD40L) were examined using multiplex xMAP technology.After 3 and 6 months of TOFA therapy, there was a significant decrease in DAS28 of 4.55 (3.47; 5.16) and 3.92 (3.80; 4.60); CDAI - 16.5 (11.0; 23.0) and 18.0 (15.0; 19.0); SDAI - 16.6 (11.23; 23.06) and 18.07 (15.06; 19.10); ESR - 19.0 (11.0; 26.0) and 7.0 (4.0; 18.0); CRP - 0.56 (0.50; 1.99) and 0.71 (0.51; 1.1) respectively. IL-6 levels decreased after 3 and 6 months of therapy (p<0.05). The concentration of INF-γ significantly decreased after 3 months (p<0.05), but remained unchanged thereafter. Concentrations of IL-25 and IL-31 decreased after 3 months (p<0.05), and by the 6th month of treatment there was an increase, however, not reaching the initial values.Conclusion. The results of the study show the efficacy of TOFA in RA and create prerequisites for further study of the cytokine-dependent mechanisms of inflammation in this disease.https://rsp.mediar-press.net/rsp/article/view/3103rheumatoid arthritistofacytokinesdisease activitymultiplex analysis |
| spellingShingle | N. A. Lapkina A. A. Baranov N. E. Abaytova N. Yu. Levshin A. S. Avdeyeva E. A. Leontyeva A. S. Artyukhov E. L. Nasonov Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy Научно-практическая ревматология rheumatoid arthritis tofa cytokines disease activity multiplex analysis |
| title | Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy |
| title_full | Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy |
| title_fullStr | Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy |
| title_full_unstemmed | Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy |
| title_short | Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy |
| title_sort | dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy |
| topic | rheumatoid arthritis tofa cytokines disease activity multiplex analysis |
| url | https://rsp.mediar-press.net/rsp/article/view/3103 |
| work_keys_str_mv | AT nalapkina dynamicsofclinicalmanifestationsandcytokineconcentrationsinrheumatoidarthritispatientsontofacitinibtherapy AT aabaranov dynamicsofclinicalmanifestationsandcytokineconcentrationsinrheumatoidarthritispatientsontofacitinibtherapy AT neabaytova dynamicsofclinicalmanifestationsandcytokineconcentrationsinrheumatoidarthritispatientsontofacitinibtherapy AT nyulevshin dynamicsofclinicalmanifestationsandcytokineconcentrationsinrheumatoidarthritispatientsontofacitinibtherapy AT asavdeyeva dynamicsofclinicalmanifestationsandcytokineconcentrationsinrheumatoidarthritispatientsontofacitinibtherapy AT ealeontyeva dynamicsofclinicalmanifestationsandcytokineconcentrationsinrheumatoidarthritispatientsontofacitinibtherapy AT asartyukhov dynamicsofclinicalmanifestationsandcytokineconcentrationsinrheumatoidarthritispatientsontofacitinibtherapy AT elnasonov dynamicsofclinicalmanifestationsandcytokineconcentrationsinrheumatoidarthritispatientsontofacitinibtherapy |